NCT05193669 (VALTRIHP) is a clinical trial in Cervical Carcinoma, sponsored by Hiantis Srl.

Who is sponsoring NCT05193669?

NCT05193669 is sponsored by Hiantis Srl.

What condition does NCT05193669 study?

NCT05193669 studies Cervical Carcinoma.

Is NCT05193669 still recruiting?

NCT05193669 is currently status unknown. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT05193669: VALTRIHP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Validation of Molecular Triage in HR-HPV Positive Women

Status unknown Last updated 8 February 2023

What this trial tests

trial in Cervical Carcinoma in 23,941 participants. Status unknown.

Timeline

14 April 2021

Primary endpoint
30 November 2022

30 November 2023

Quick facts

Lead sponsor	Hiantis Srl
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	23,941
Start date	14 April 2021
Primary completion	30 November 2022
Estimated completion	30 November 2023
Sites	1 location across Italy

Conditions studied

Cervical Carcinoma — all drugs for Cervical Carcinoma →

Sponsor

Hiantis Srl

Who can join

Adults 25 to 64, female only, with Cervical Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Women accessing the HPV-based screening programme for primary screening, will undergo cervical sampling and clinical data recording. Samples from high-risk HPV positive women (around 2000 expected) will be aliquoted for testing with new HPV molecular test, that will allow full genotyping and viral load quantification.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cervical Carcinoma

Currently open trials in the same condition.

NCT07407647 — Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer · Phase 2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
NCT06804135 — Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting

Other Hiantis Srl trials

Trials by the same sponsor.

NCT04312737 — Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05193669 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hiantis Srl
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05193669.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing